866-997-4948(US-Canada Toll Free)

Amaryl (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 44 Pages


GlobalDatas pharmaceuticals report, Amaryl (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Amaryl sales estimates for US, EU-5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US.
  • Analysis and review ofAmaryl including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Amaryl including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Amaryl in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 20

6.1 Insulin 20
6.2 Oral Medications 20
6.2.1 Sulfonylureas (SUR) 20
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 22
6.2.4 Meglitinides 22
6.2.5 Thiazolidinediones (TZDs) 23
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 24
6.2.7 Oral Combination Therapy 24
6.3 Other Injectionable Medications 25
6.3.1 Pramlintide 25
6.3.2 Exenatide 25
6.4 Market Share as per Classes in Type 2 Diabetes 25

7 Amaryl 26
7.1 Introduction 26
7.2 Mechanism of Action 26
7.3 Clinical Studies 26
7.3.1 A Phase III Clinical Study to Test the Safety and Effectiveness of Amaryl among Different Age Groups 26
7.3.2 Amaryl as a Monotherapy 26
7.3.3 Amaryl in Combination with Metformin 27
7.3.4 Amaryl in Combination with Insulin 27
7.4 Approval History of Amaryl 28
7.5 Factors Affecting Sales of Amaryl 28
7.5.1 Weight Neutral or Weight Gain 28
7.5.2 Market Presence 28
7.5.3 Low Impact of Patent Expiry on Amaryl Sales 28
7.5.4 Potential Benefits 28
7.5.5 First Mover Advantage 29
7.5.6 Launch of Amaryl M 29
7.6 Drug Evaluation 29
7.6.1 Drug Risk Benefit Score 29
7.6.2 Intensity of Competition 30
7.7 Sales Estimates 31
7.7.1 Target Patient Pool for Amaryl 31
7.7.2 Dosing 31
7.7.3 Market Penetration 31
7.7.4 Annual Cost of Therapy 31
7.7.5 Sales Projections of Amaryl 31

8 Type 2 Diabetes Market: Appendix 41
8.1 Market Definitions 41
8.2 List of Abberiviations 41
8.3 Research Methodology 41
8.3.1 Coverage 42
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Net Penetration of Drug 42
8.3.5 Net Annual Dosing 43
8.3.6 Annual Cost of Therapy 43
8.3.7 Primary Research 43
8.3.8 Expert Panels 43
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 44
8.6 Disclaimer 44
8.7 Sources 44

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 19
Table 9: Amaryl Efficacy details in various dosages 27
Table 10: Amaryl Approval History 28
Table 11: Drug Risk Benefit Score 29
Table 12: Amaryl, Type 2 Diabetes, Global, Sales Estimates ($m), 20022020 32
Table 13: Amaryl, Type 2 Diabetes, The US, Sales Estimates ($m), 20022015 33
Table 14: Amaryl, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022017 34
Table 15: Amaryl, Type 2 Diabetes, France, Sales Estimates ($m), 20022017 35
Table 16: Amaryl, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022017 36
Table 17: Amaryl, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022017 37
Table 18: Amaryl, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022017 38
Table 19: Amaryl, Type 2 Diabetes, Japan, Sales Estimates ($m), 20022020 39

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 
Figure 3: Diabetes, World, Mortality, 2010 
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020 
Figure 6: Mechanism of Action of Sulfonylureas 
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 
Figure 9: Mechanism of Action of Thiazolidinediones 
Figure 10: Mechanism of Action of DPP IV Inhibitors 
Figure 11: Type 2 Diabetes, Global, Branded Market Share By Class (%), 2010 
Figure 12: Amaryl, Type 2 Diabetes, Global, Sales Estimates ($m), 2002–2020 
Figure 13: Amaryl, Type 2 Diabetes, The US, Sales Estimates ($m), 2002–2015 
Figure 14: Amaryl, Type 2 Diabetes, The UK, Sales Estimates ($m), 2002–2017 
Figure 15: Amaryl, Type 2 Diabetes, France, Sales Estimates ($m), 2002–2017 
Figure 16: Amaryl, Type 2 Diabetes, Germany, Sales Estimates ($m), 2002–2017 
Figure 17: Amaryl, Type 2 Diabetes, Italy, Sales Estimates ($m), 2002–2017 
Figure 18: Amaryl, Type 2 Diabetes, Spain, Sales Estimates ($m), 2002–2017 
Figure 19: Amaryl, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002–2020 
Figure 20: Amaryl, Type 2 Diabetes, Sales Distribution by Country (%), 2004 
Figure 21: Patients Approved for the Drug 

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *